The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Chiptune is a genre that developed from reusing the onboard synth generation chips in classic gaming consoles such as ...

NerdWallet receives compensation of 0% to 0.85% of assets under management annualized, payable monthly, for each referred client who opens an Atomic account and a percentage of free cash interest ...

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

O n any given day, millions of people in the U.S. are trying to lose weight. Recent data from the Centers for Disease Control and Prevention reports that a little over 40% of adul ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Eli Lilly and Novo Nordisk have been competing in the obesity market for the past year, making it an opportune time to review the benefits of the two most prominent obesity medications.

GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound — mimic at least one hormone produced by the gut to signal fullness, leading to a reduced appetite.

Exercise includes cardio and strength training, which together support heart health, healthy blood sugar levels, and weight ...

Starting in the new year, Independence Blue Cross, the region’s largest health insurer, will no longer cover anti-obesity drugs like Ozempic and Wegovy when they’re prescribed solely for weight loss.